Navigation Links
Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions
Date:6/28/2011

HAYWARD, Calif., June 28, 2011 /PRNewswire/ -- Intarcia Therapeutics, Inc. announced  today the presentation of final 48-week results of a phase 2 clinical study of ITCA 650 (DUROS® subcutaneous continuous delivery of exenatide) for the treatment of type 2 diabetes at the American Diabetes Association's 71st Scientific Sessions in San Diego, California.

(Logo:  http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO)

Results of the phase 2 study, presented by Julio Rosenstock, M.D., Director of the Dallas Diabetes and Endocrine Center at Medical City and Clinical Professor of Medicine at the University of Texas Southwestern Medical School, demonstrated that patients receiving treatment with ITCA 650 experienced substantial and sustained reductions in HbA1c, fasting plasma glucose (FPG) and body weight during the 48 weeks of treatment at all doses. A starting dose of ITCA 650 20 mcg/day for weeks 1 through 12 provided improved glycemic control with the best tolerability profile. Subsequent transition to ITCA 650 doses of 40, 60 or 80 mcg/day led to statistically significant improvements in HbA1c, FPG and body weight after 24 and 48 weeks of treatment.  

"We are very encouraged by the robust results observed in this study and the high level of enthusiasm expressed by patients and investigators," said Kurt Graves, Executive Chairman of the Board of Directors of Intarcia. "ITCA 650 is a novel GLP-1 therapeutic approach for type 2 diabetes that holds new promise for many patients and physicians who want robust glucose reductions and a favorable weight profile without the trade-offs associated with having to start potentially life-long and frequent self-injections." Graves added, "ITCA 650 not only delivers sustained glycemic control and favorable weight effects but the breakthrough subcutaneous continuous delivery platform is being developed as just a once-
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference
2. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
3. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
4. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
5. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
6. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
7. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
8. SVS 2011: Ziehm Imaging Presents Latest Mobile C-armTechnology for Intraoperative use
9. Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinsons Disease at International Neuromodulation Society 10th World Congress
10. Tolerx Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
11. TGen and PBS-Bio presents 2 abstracts at AACR conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... 2014 This report covers ... in the life science industry. Continuous innovation ... reagents market towards remarkable growth. The stakeholders ... of life science reagents. , Brows full ... . , The global life science reagents ...
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, a ... that are used solely in scientific experiments, is currently ... years in business, Maxim Peptide, which was created by ... a new and updated website that now features a ... has been updated with fascinating articles about peptide research, ...
(Date:7/11/2014)... 11, 2014 , Not for release, ... or from any jurisdiction where to do so would constitute ... Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ...  Shire confirms it has held a meeting with representatives of ... without the prior agreement or approval of AbbVie. ...
(Date:7/11/2014)... , July 11, 2014 Research ... "International Transfection Technology Market - Global Industry Analysis, Size, ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... introduce nucleic acids (either DNA or RNA) into cells. ... mutation of cancer cells and protein metabolism by affecting ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Shire plc - Statement re: Media Speculation 2International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2
... 7 When leading contract research,organization Pharm-Olam International (POI, ... voice-over Internet protocol (VoIP),system that would better serve the ... catastrophic., POI initially selected a local vendor to ... immediately clear the solution was a bigger problem,than the ...
... LifeQuest World Corporation,(OTC Bulletin Board: LQWC) is pleased ... ImmunXT, their Immune System enhancement supplement, has,been released ... of March 2008.,ImmunXT has been proclaimed as "the ... (US Patent #7,205,284 B2),is a bio-active Micro-algae Complex ...
... Eastern Time -, SOUTH SAN FRANCISCO, Calif., May ... biopharmaceutical company focused,on oncology, today reported on its corporate ... 31, 2008., "During the first quarter, we made ... data to demonstrate the potential of,picoplatin as a new ...
Cached Biology Technology:Pharm-Olam Finds VoIP Solution in Taridium LLC 2LifeQuest World Launches Immune System Boosting Supplement to the North American Market 2Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 2Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 3Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 4Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 5Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 6Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 7Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 8Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 9
(Date:7/11/2014)... A new report from the Wildlife Conservation Society ... only help economically valuable species such as lobster, ... also help re-colonize nearby reef areas. , The ... a systematic review of research literature from no-take ... by Dr. Craig Dahlgren, a recognized expert in ...
(Date:7/11/2014)... at the Department of Energy,s Oak Ridge National ... by R&D Magazine in recognition of the year,s ... the tremendous value of our National Labs," said ... at the National Labs continues to help our ... scientific and technological innovations necessary to remain globally ...
(Date:7/11/2014)... eastern New South Wales, Australia when NASA,s Aqua satellite ... on July 11 (12:35 p.m. local time/11:35 p.m. EDT ... South Wales (NSW), the Moderate Resolution Imaging Spectroradiometer (MODIS) ... and spotted smoke (light brown) from various fires. Actively ... in red. , The New South Wales, Australia Government ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... and treatment of breast cancer, the disease remains a ... technology under investigation at the Biodesign Institute at Arizona ... cell nuclear structure, the molecular biosignature of cancer, thus ... detection of the disease. The team, led by ...
... half years since Adam Bogdanove, professor at Iowa State University ... Matthew Moscou, a former graduate student in that department, discovered ... and bind specific sequences in plant genomes, researchers worldwide have ... was first shown that the proteins can be fused to ...
... Scientists have uncovered a lot about the Earth,s greatest ... rapid climate change wiped out nearly all marine species and ... a new culprit likely involved in the annihilation: an influx ... looked to see if mercury was a potential culprit. This ...
Cached Biology News:Cell-CT: A new dimension in breast cancer research 2Cell-CT: A new dimension in breast cancer research 3Cell-CT: A new dimension in breast cancer research 4ISU scientist helps find structure of gene-editing protein named Method of the Year 2Earth's massive extinction: The story gets worse 2